Pharmacogenetic considerations in the treatment of Alzheimer's disease
| dc.contributor.author | Cacabelos, Ramón | |
| dc.contributor.author | Torrellas, Clara | |
| dc.contributor.author | Teijido Hermida, Óscar | |
| dc.contributor.author | Carril, Juan Carlos | |
| dc.contributor.department | Ciencias de la Salud | es_ES |
| dc.contributor.department | Osasun Zientziak | eu |
| dc.date.accessioned | 2025-04-01T16:02:33Z | |
| dc.date.available | 2025-04-01T16:02:33Z | |
| dc.date.issued | 2016 | |
| dc.date.updated | 2025-04-01T15:49:04Z | |
| dc.description | Acceso cerrado a este documento. No se encuentra disponible para la consulta pública. Depositado en Academica-e para cumplir con los requisitos de evaluación y acreditación académica del autor/a (sexenios, acreditaciones, etc.). | |
| dc.description.abstract | The practical pharmacogenetics of Alzheimer’s disease (AD) is circumscribed to acetylcholinesterase inhibitors (AChEIs) and memantine. However, pharmacogenetic procedures should be applied to novel strategies in AD therapeutics including: novel AChEIs and neurotransmitter regulators, anti-Aβ treatments, anti-tau treatments, pleiotropic products, epigenetic drugs and combination therapies. Genes involved in the pharmacogenetic network are under the influence of the epigenetic machinery which regulates gene expression transcriptionally and post-transcriptionally, configuring the fundamentals of pharmacoepigenomics. Over 60% of AD patients present concomitant pathologies demanding additional treatments which increase the likelihood of drug–drug interactions. Lipid metabolism dysfunction is a pathogenic mechanism inherent to AD neurodegeneration. The therapeutic response to hypolipidemic compounds is influenced by the APOE and CYP genotypes. The development of novel compounds and the use of combination/multifactorial treatments require the implantation of pharmacogenomic procedures for the avoidance of ADRs and the optimization of therapeutics. | en |
| dc.description.sponsorship | Experimental data were supported by EuroEspes S.A. and the International Agency for Brain Research and Aging (IABRA). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. | |
| dc.format.mimetype | application/pdf | en |
| dc.identifier.citation | Cacabelos, R., Torrellas, C., Teijido, O., Carril, J. C. (2016) Pharmacogenetic considerations in the treatment of Alzheimer's disease. Pharmacogenomics, 17(9), 1041-1074. https://doi.org/10.2217/pgs-2016-0031. | |
| dc.identifier.doi | 10.2217/pgs-2016-0031 | |
| dc.identifier.issn | 1462-2416 | |
| dc.identifier.uri | https://academica-e.unavarra.es/handle/2454/53889 | |
| dc.language.iso | eng | |
| dc.publisher | Taylor & Francis | |
| dc.relation.ispartof | Pharmacogenomics, 2016, 17(9), 1041–1074 | |
| dc.relation.publisherversion | https://doi.org/10.2217/pgs-2016-0031 | |
| dc.rights | © 2016 Future Medicine Ltd. | |
| dc.rights.accessRights | info:eu-repo/semantics/closedAccess | |
| dc.subject | Alzheimer's disease | en |
| dc.subject | Antidementia drugs | en |
| dc.subject | APOE | en |
| dc.subject | CYPs | en |
| dc.subject | Drug interactions | en |
| dc.subject | Epigenetics | en |
| dc.subject | Lipid metabolism dysfunction | en |
| dc.subject | Pharmacoepigenomics | en |
| dc.subject | Pharmacogenomics | en |
| dc.subject | Transporters | en |
| dc.title | Pharmacogenetic considerations in the treatment of Alzheimer's disease | en |
| dc.type | info:eu-repo/semantics/article | |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 2af87636-fad2-48e3-b5f6-f4a704d93613 | |
| relation.isAuthorOfPublication.latestForDiscovery | 2af87636-fad2-48e3-b5f6-f4a704d93613 |